Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Phase 3 Data Show RYBREVANT + LAZCLUZE Outperforms Osimertinib In Non-small
Johnson & Johnson announced that RYBREVANT (amivantamab-vmjw) combined with LAZCLUZE (lazertinib) provided consistent benefits over osimertinib in advanced NSCLC patients with EGFR exon 19 deletions or L858R mutations, with 61% survival at three years compared to 53% for osimertinib. The combination also showed improved central nervous system disease control and longer progression-free survival.
Global Orphan Drugs Market with Market Share, Growth, Trends Analysis by 2024-2032
The Orphan Drugs Market is projected to grow from USD 225.9 Billion in 2023 to USD 493.21 Billion by 2031, driven by rising prevalence of rare diseases, unmet medical needs, favorable regulatory policies, technological advancements, and growing public and patient advocacy. Key challenges include high R&D costs, limited patient populations, pricing and reimbursement issues, and lack of long-term data. Trends include focus on gene therapies, personalized medicine, stakeholder collaboration, and expansion into emerging markets. North America leads the market, followed by Europe and Asia Pacific.
Global Prostate Cancer Treatment Market Size - By Product
Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.
Ultrasound And Electrosurgical Energy Dissectors Market Projected Growth Outlined by
The ultrasound and electrosurgical energy dissectors market is projected to reach $8.48 billion by 2028 with a CAGR of 7.1%, driven by factors like point-of-care diagnostics, robotic surgeries, and outpatient procedures. Key players include Johnson & Johnson, Medtronic, and Olympus Corporation. Market segments include ultrasound and electrosurgical devices, applications in cardiology, gynecology, and general surgery, and end-users such as hospitals and ambulatory surgical centers.
RYBREVANT ® (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
Longer-term MARIPOSA study data show RYBREVANT® plus LAZCLUZE™ outperforms osimertinib monotherapy in first-line treatment for EGFR-mutant NSCLC, with improved survival and CNS disease control at three years. Presented at WCLC 2024.
Related Clinical Trials:
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable ...
MARIPOSA study shows RYBREVANT® plus LAZCLUZE™ provides superior outcomes vs osimertinib in first-line EGFR-mutant NSCLC, with improved overall survival and CNS disease control.
Related Clinical Trials:
Mpox global outbreak leads to significant increases in pharmaceutical stock markets
The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.
© Copyright 2025. All Rights Reserved by MedPath